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Sleep-Time Blood Pressure
A Validated Therapeutic Target*
Alan H. Gradman, MD
Pittsburgh, Pennsylvania
The objective of treating hypertension is to reduce blood
pressure (BP) in a manner that diminishes or, ideally,
abolishes the cardiovascular (CV) risks associated with BP
elevation. The epidemiologic relationship between BP and
CV risk is consistent, whether BP is measured at random in
the clinic, home, workplace, or over 24 h with intermittent
or continuous BP monitoring. The salutary effect of BP
reduction is likewise consistent and, to a large extent,
independent of the interventions used to achieve it. Unfor-
tunately, antihypertensive therapy as currently practiced
does not eliminate the hazards associated with BP elevation.
Rather, it decreases them by approximately one-third, a
worthwhile but clearly suboptimal result.
See page 1165
Attempts to refine estimates of risk have focused, in part, on
the use of out-of-office BP monitoring to increase the sample
size of BP measurements and provide an accurate estimate of
the habitual pressure load to which the vasculature is exposed.
Prospective studies indicate that the average of repeated BP
measurements is superior to clinic BPs in predicting the
development of hypertension-related structural abnormalities
such as left ventricular hypertrophy and the occurrence of
major CV events, including stroke and myocardial infarction
(1). The long-term advantage of therapy directed at these
argets has not been demonstrated, however, and the substitu-
ion of BP averages for random readings does not change the
asic assumption of hypertension treatment—that lower is
etter so long as diastolic BP is sufficient to maintain coronary
erfusion. According to the current paradigm, an effective
harmacological regimen is one that provides continuous,
ndiscriminate BP reduction 24 h/day. The report by Hermida
t al. (2) in this issue of the Journal, challenges conventional
isdom and, in so doing, has the potential to effect important
hanges in the management of hypertension.
*Editorials published in the Journal of the American College of Cardiology reflect the
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contents of this paper to disclose.Their results are derived from the MAPEC (Monitor-
zacio´n Ambulatoria para Prediccio´n de Eventos Cardiovas-
ulares) study, a prospective single-center PROBE study
hat enrolled 3,344 normotensive and hypertensive subjects.
he rationale for the MAPEC study originates from anal-
ses of 24-h BP recordings that indicate that the timing of
P elevation as well as the integrated BP “burden” is
mportant in determining CV risk. In most individuals
normotensive or hypertensive), BP has a predictable circa-
ian pattern characterized by a rapid increase at the time of
wakening, with maximum levels reached during the morn-
ng hours and maintained until an evening BP decline
eaches its nadir during sleep.
The normal reduction in BP during sleep is approxi-
ately 10% to 20%. In 1988, O’Brien et al. (3) coined the
erm “nondipper” to describe a subgroup of hypertensive
atients in whom the nocturnal BP decline was 10/5 mm
g and reported that the risk of stroke in these patients was
arkedly elevated. Although subsequent investigators used
ariable definitions of “dipping” and “nondipping,” the
dverse prognostic implications of reduced nocturnal BP
ecline has proved a durable finding. In a prospective study,
erdecchia (1) reported that “nondippers” experienced nearly 3
imes as many CV events as “dippers.” Other sources have
onfirmed an increased risk of stroke, myocardial infarction,
rogressive renal insufficiency, and heart failure as well as
ncreased prevalence of left ventricular hypertrophy/diastolic
ysfunction, microalbuminuria, and endothelial dysfunction in
nondippers” compared with “dippers” (4).
The MAPEC study was designed to determine the prog-
ostic significance of pre-specified aspects of the 24-h BP
rofile and evaluate changes in circadian BP patterns on the
requency of CV events. The authors report that baseline
mbulatory blood pressure monitoring (ABPM) parameters
ncluding mean daytime systolic blood pressure (SBP), night-
ime SBP, and reduction in SBP during sleep correlated better
ith the occurrence of CV endpoints (n 331) than clinic BP
ver a median follow-up of 5.6 years. These findings are in
ccordance with earlier studies. What is new is their observa-
ion that a specific alteration in the circadian BP pattern
esulted in a significant reduction in CV endpoints. Thus, a
3% decrease in CV risk was observed for every 5-mm Hg
ecline in asleep BP (p  0.001), and this risk reduction was
ndependent of changes in other aspects of the circadian BP
attern. Reduction in the level of BP during sleep and the
ifference in sleep/waking BP were the most potent predictors
f future events. Reduction in mean 48-h SBP was inferior as
therapeutic target and was not associated with improved
utcomes in statistical models that incorporated measurements
f asleep BP.
Therefore, sleep-time BP qualifies as a validated target of
ntihypertensive therapy. The authors suggest that treatment
hould be directed routinely at nocturnal BP and that this goal
s best accomplished by nighttime administration of antihyper-
ensive medications. In the MAPEC study, hypertensive
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September 6, 2011:1174–5 Sleep-Time Blood Pressurepatients were randomized to receive all of their medications in
the morning or to ingest 1 or more at bedtime. In a previous
paper, the authors reported that patients receiving at least some
of their medications at bedtime had a significantly lower
relative risk (RR) of total CV events, compared with those
taking all of their medications upon awakening (RR: 0.39, 95%
confidence interval: 0.29 to 0.51, p 0.001). Reduction in the
RR of major events (CV death, myocardial infarction, and
stroke) was also highly significant (RR: 0.33, 95% confidence
interval: 0.19 to 0.55, p  0.001). No adverse effects were
attributed to nocturnal drug administration (5).
The critical importance of reducing sleep-time BP might
explain, at least in part, the problematic results of several
earlier studies. In the ACCORD (Action to Control Car-
diovascular Risk in Diabetes) study, for example, aggressive
overall BP reduction did not improve CV outcomes in
diabetic patients (6). In the MAPEC study, reduction of
mean 48-h BP was not associated with significant risk
reduction in statistical models that incorporated asleep BP.
In the CONVINCE (Controlled Onset Verapamil Investiga-
tion of Cardiovascular Endpoints), a timed-release formulation
of verapamil that targeted the early-morning rise in BP failed
to show an advantage over conventional AM administration of
atenolol/hydrochlorothiazide (7). In the present study, dimi-
nution of the early-morning rise in BP had no effect on CV
events. In the HOPE (Heart Outcomes Prevention Evalua-
tion) study, the marked reduction in CV endpoints—
seemingly out of proportion to the modest changes observed in
clinic BP—could perhaps be explained by the protocol-
specified administration of the study drug (ramipril) at bed-
time. This hypothesis is supported by the marked reduction in
nocturnal BP reported in a small ABPM substudy of HOPE
(8) as well as data from the present study group demonstrating
hat bedtime administration of ramipril results in superior
octurnal BP regulation without compromising antihyperten-
ive efficacy during the waking hours (9).
The implications of these findings for clinical practice are
ubstantial. A strong case can be made to accept the
onclusion of the authors that bedtime administration of at
east some portion of the antihypertensive regimen of the
atient should become the default standard. Previous stud-
es with a number of drugs from different pharmacological
lasses have compared the antihypertensive effects of night-
ime versus morning dosing. For most drugs, nighttime
dministration produces similar changes in mean 24-h BP,
ompared with morning dosing, and there is little loss of
aytime BP control. Bedtime administration is consistently
ore effective in reducing BP during sleep, increasing the
agnitude of sleep-time BP reduction, and reducing the
ercentage of “non-dippers,” irrespective of the pharmaco-
ogical half-life of the agent tested (9).
It should be noted, however, that the clinical approach used
n the MAPEC study was atypical in that therapy was
outinely directed toward normalization of the circadian BP
attern. In addition to randomizing patients to morning versus
edtime drug administration, drug therapy was further ad-usted based on analysis of repeated 48-h ABPM recordings.
he benefits of this overall approach to treatment have not
een documented, and application of this labor-intensive
ethodology to the routine management of hypertension
ould add considerable costs to the healthcare system.
The ideal result would be to use the insights gained from
his and other studies and achieve the benefits of reducing
sleep BP without performing repeated ABPM in every
atient. To do so, the safety of routine nighttime drug
dministration must be clearly established. Bedtime drug
dministration raises the possibility of nocturnal hypoten-
ion, which has been reported to cause both cerebral and
yocardial ischemia in susceptible patients. Although this
isk seems to be small or nonexistent based on the totality of
vailable evidence, it might be significant in certain sub-
roups (e.g., patients with coronary artery disease in whom
oronary perfusion might be compromised by nocturnal
ypotension). Further studies will be required to establish
he safety of routine nighttime drug administration in such
atients; alternatively, ABPM can be used in individual
ases. In any event, identification of sleep-time BP as a valid
herapeutic target constitutes an important milestone in the
volution of antihypertensive therapy. The mere suggestion
hat CV event rates in patients with hypertension can be
educed by more than 50% with a zero-cost strategy of
iving existing medications at bedtime rather than in the
orning is nothing short of revolutionary.
Reprint requests and correspondence: Dr. Alan H. Gradman,
Temple University School of Medicine, 1239 Shady Avenue,
Pittsburgh, Pennsylvania 15232. E-mail: gradmana@temple.edu.
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